Develops immunotherapies for cancer and autoimmune diseases.
Jun 2026Revenue $6.19M/yrExpenses $20.4M/yr
No trendCash runway ≈ 5 months from Jun 2026
Figures by year
When will Atara Biotherapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $6.19M and expenses $20.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $121M | $84.9M | $35.9M |
| Dec 2024 | $129M | $212M | −$83.4M |
| Dec 2023 | $8.57M | $285M | −$276M |
| Dec 2022 | $63.6M | $344M | −$281M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.